Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model - China, 2025.

IF 2.9 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

中国疾病预防控制中心周报 Pub Date : 2025-09-26 DOI:10.46234/ccdcw2025.209

Yixiang Ma, Zixin Fang, Xiaoyan Tao, Shuqing Liu, Qian Liu, Minghui Zhang, Pengcheng Yu, Si Liu, Wuyang Zhu

{"title":"Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model - China, 2025.","authors":"Yixiang Ma, Zixin Fang, Xiaoyan Tao, Shuqing Liu, Qian Liu, Minghui Zhang, Pengcheng Yu, Si Liu, Wuyang Zhu","doi":"10.46234/ccdcw2025.209","DOIUrl":null,"url":null,"abstract":"What is already known about this topic?: Rabies is a fatal, but preventable, viral disease. Post-exposure prophylaxis (PEP), which includes the administration of passive immune preparations, is critical after exposure to the rabies virus, particularly in high-risk cases. The delayed or missed application of passive immunizing agents may increase the risk of infection.What is added by this report?: SYN023, a novel anti-rabies monoclonal antibody cocktail, can effectively reverse the course of rabies infection, even at a late stage of the disease. In a mouse model infected with the rabies virus strain SC16, multiple high-dose injections of SYN023 administered 5 days post-inoculation rescued 69% of the animals.What are the implications for public health practice?: These findings suggest that SYN023 could serve as a promising therapeutic agent for rabies PEP, particularly in cases in which treatment initiation is delayed. This study provides a scientific basis for future clinical trials aimed at improving rabies treatment protocols.","PeriodicalId":69039,"journal":{"name":"中国疾病预防控制中心周报","volume":"7 39","pages":"1241-1245"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518970/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国疾病预防控制中心周报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46234/ccdcw2025.209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

What is already known about this topic?: Rabies is a fatal, but preventable, viral disease. Post-exposure prophylaxis (PEP), which includes the administration of passive immune preparations, is critical after exposure to the rabies virus, particularly in high-risk cases. The delayed or missed application of passive immunizing agents may increase the risk of infection.

What is added by this report?: SYN023, a novel anti-rabies monoclonal antibody cocktail, can effectively reverse the course of rabies infection, even at a late stage of the disease. In a mouse model infected with the rabies virus strain SC16, multiple high-dose injections of SYN023 administered 5 days post-inoculation rescued 69% of the animals.

What are the implications for public health practice?: These findings suggest that SYN023 could serve as a promising therapeutic agent for rabies PEP, particularly in cases in which treatment initiation is delayed. This study provides a scientific basis for future clinical trials aimed at improving rabies treatment protocols.

查看原文本刊更多论文

SYN023在小鼠狂犬病模型中的病毒清除效果评价-中国，2025。

关于这个话题我们已经知道了什么？狂犬病是一种致命但可预防的病毒性疾病。暴露后预防（PEP），包括被动免疫制剂的使用，在接触狂犬病毒后至关重要，特别是在高危病例中。延迟或错过被动免疫剂的应用可能会增加感染的风险。这份报告增加了什么内容？： SYN023是一种新型抗狂犬病单克隆抗体鸡尾酒，即使在疾病晚期也能有效逆转狂犬病感染的过程。在感染狂犬病毒SC16株的小鼠模型中，接种后5天多次高剂量注射SYN023, 69%的动物获救。这对公共卫生实践有什么影响？这些发现表明SYN023可以作为狂犬病PEP的一种有希望的治疗剂，特别是在治疗开始延迟的情况下。本研究为进一步完善狂犬病治疗方案的临床试验提供了科学依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国疾病预防控制中心周报

CiteScore

5.90

自引率

0.00%

发文量